Posted by Michael Wonder on 19 Jan 2023
Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of Tascenso ODT (fingolimod)
17 January 2023 - Tascenso ODT is now approved by the US FDA as a bioequivalent to Gilenya (fingolimod hydrochloride), for which patient support program will be withdrawn in 2023.
Cycle Pharmaceuticals has today welcomed the news that multiple sclerosis patients in the US currently being treated with Gilenya, or generic fingolimod hydrochloride to have access to appropriate patient support services alongside the bioequivalent, Tascenso ODT following the withdrawal of Gilenya patient support on 31 March 2023.
